Modulus Therapeutics

Modulus Therapeutics is a Seattle-based cellular therapy startup spun out of the Allen Institute for Artificial Intelligence (AI2) that...

Facts

HQ
Seattle
Sectors
Biotechnology, Cellular therapy, Machine learning, Healthcare
Type
Corporation Seattle business license
Registered name
Modulus Therapeutics Inc Seattle business license
Stage
Seed
Total raised
$3.8M SEC Form D filings Total of this company's SEC Form D filings
Last round
$3.8M · Jul 2021 SEC Form D

Augment AI, Led by Napster Co-Founder Jordan Ritter, Launches Private Beta of AI-Powered Productivity Tools After $3.5M Seed Round

Seattle startup Augment AI, spun out of AI2 and led by Napster co-founder Jordan Ritter, has launched a private beta of its AI-powered productivity sidekick designed to take meeting notes and organize research. The company raised $3.5 million in seed funding and offers two apps, Meeting Augment and Memory Augment, to enhance workflow integration with tools like Zoom.

Andreessen Horowitz, Madrona and other tech VCs ramp up bets on AI-driven biotech startups as founders from software enter life sciences

Tech venture capital firms like Andreessen Horowitz and Seattle’s Madrona Venture Group are increasingly investing in life-science startups that use AI, machine learning and data science to speed drug discovery and development. Investors are following founders who transitioned from software to biotech—such as Sujal Patel of Nautilus and Terry Myerson of Truveta—seeing reduced perceived risk and new opportunity at this intersection.

AI2 Spinout BirchAI Raises $3.1M Seed to Automate Healthcare Customer-Support Call Summaries

BirchAI, an AI2 spinout founded in June 2020, raised $3.1 million in seed funding for software that transcribes, summarizes and analyzes healthcare customer-support calls to reduce post-call documentation time and improve employee and patient satisfaction. CEO Kevin Terrell says the Seattle startup targets medical device, pharmaceutical and insurance companies and lets employees edit AI-generated summaries.

Modulus Therapeutics, spun out of the Allen Institute for AI, raises $3.5M to engineer enhanced NK cell therapies

Modulus Therapeutics, a Seattle cell-therapy startup spun out of the Allen Institute for AI, raised $3.5 million in seed funding to use lab research and machine learning to engineer enhanced natural killer (NK) cells for anti-tumor therapies. Founders Max Darnell and Bryce Daines aim to develop a discovery platform to generate NK cell product candidates for larger cellular therapy companies.